Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADT ± darolutamide in vulnerable de novo metastatic prostate cancer (phase III, double-blind randomized)
2020-003663-26Phase 3Active
- Sponsor
- Unicancer
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) and prostate adenocarcinoma comparing ADT + darolutamide with ADT + placebo (2 arms). Primary endpoint: Radiographic progression-free survival. Started Jun 2021; status: active.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on 2020-003663-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003663-26.